These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36662612)

  • 1. Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.
    Jiang N; Xiao Y; Yuan K; Wang Z
    J Gastroenterol Hepatol; 2023 Jul; 38(7):1056-1071. PubMed ID: 36662612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gut microbiota-bile acid axis in cholestatic liver disease.
    Sun D; Xie C; Zhao Y; Liao J; Li S; Zhang Y; Wang D; Hua K; Gu Y; Du J; Huang G; Huang J
    Mol Med; 2024 Jul; 30(1):104. PubMed ID: 39030473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.
    Hendrikx T; Schnabl B
    J Intern Med; 2019 Jul; 286(1):32-40. PubMed ID: 30873652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between the intestinal microbiome and liver diseases.
    Schnabl B; Brenner DA
    Gastroenterology; 2014 May; 146(6):1513-24. PubMed ID: 24440671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
    Chopyk DM; Grakoui A
    Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Microbiota: What Do We Know about It at Present?
    Derovs A; Laivacuma S; Krumina A
    Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31405111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.
    Woodhouse C; Singanayagam A; Patel VC
    Clin Med (Lond); 2020 Sep; 20(5):493-500. PubMed ID: 32934044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gut-liver axis and gut microbiota in health and liver disease.
    Hsu CL; Schnabl B
    Nat Rev Microbiol; 2023 Nov; 21(11):719-733. PubMed ID: 37316582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gut-liver axis in immune remodeling of hepatic cirrhosis.
    Guan H; Zhang X; Kuang M; Yu J
    Front Immunol; 2022; 13():946628. PubMed ID: 37408838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
    Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
    Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal microbiota dysbiosis in acute kidney injury: novel insights into mechanisms and promising therapeutic strategies.
    Lei J; Xie Y; Sheng J; Song J
    Ren Fail; 2022 Dec; 44(1):571-580. PubMed ID: 35350960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.
    Maslennikov R; Poluektova E; Zolnikova O; Sedova A; Kurbatova A; Shulpekova Y; Dzhakhaya N; Kardasheva S; Nadinskaia M; Bueverova E; Nechaev V; Karchevskaya A; Ivashkin V
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
    Brandl K; Schnabl B
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1069-76. PubMed ID: 26088524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage.
    Plaza-Díaz J; Solís-Urra P; Rodríguez-Rodríguez F; Olivares-Arancibia J; Navarro-Oliveros M; Abadía-Molina F; Álvarez-Mercado AI
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
    Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysbiosis and liver diseases (Review).
    Nishikawa H; Fukunishi S; Asai A; Yokohama K; Ohama H; Nishiguchi S; Higuchi K
    Int J Mol Med; 2021 Sep; 48(3):. PubMed ID: 34328191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the gut microbiota in type 2 diabetes and related diseases.
    Yang G; Wei J; Liu P; Zhang Q; Tian Y; Hou G; Meng L; Xin Y; Jiang X
    Metabolism; 2021 Apr; 117():154712. PubMed ID: 33497712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.